XILIS, Inc. news
Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that it is participating in the recently announced public-private Oncode-PACT. Led by the Netherlands-based Oncode Institute, the consortium will be supported by the National Growth Fund, an initiative of the Dutch Ministry of Economic Affairs and Climate Policy and the Ministry of Finance
Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that breast cancer oncologist Daniel F. Hayes, MD, FACP, FASCO, has joined the company’s Clinical Advisory Board (CAB).
Dr. Hayes is a Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at
- Xilis’ MicroOrganoSphere™ (MOS) technology generates thousands of miniature patient- derived tumors that capture the original heterogeneity and microenvironment for therapeutic profiling
- The company’s platform can deliver personalized precision treatment strategies for patients and accelerate drug discovery and development for pharmaceutical companies